Physician profile
Hamid Ullah
NPI 1851725022
$1,696.27
in general payments reported to CMS, 2019-2025
21 companies · $507 in 2025
The $507 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $57.84 · 2020: $29.18 · 2021: $92.03 · 2022: $38.63 · 2023: $156 · 2024: $815 · 2025: $507.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,430 · Education: $48.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,429.64 |
| Education | $48.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $362.08 | 2019-2024 | |
| Janssen Scientific Affairs, LLC | $331.22 | 2023-2025 | Stelara |
| Janssen Biotech, INC. | $202.42 | 2023-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $130.05 | 2024-2025 | Entyvio, Gattex |
| Olympus America INC. | $124.50 | 2025 | Single Use Electrosurgical Knife Kd-655 |
| Micro-Tech Endoscopy USA, INC. | $89.18 | 2024 | Eyemax |
| Ardelyx, INC. | $62.22 | 2024 | Ibsrela |
| Gilead Sciences, INC. | $51.64 | 2024 | |
| Mallinckrodt Hospital Products INC. | $47.39 | 2025 | Terlivaz |
| Novartis Pharmaceuticals Corporation | $46.76 | 2019 | |
| Abbvie INC. | $34.56 | 2025 | |
| Madrigal Pharmaceuticals | $31.59 | 2025 | Rezdiffra |
| Aimmune Therapeutics, INC. | $29.92 | 2025 | Zenpep |
| Pfizer INC. | $29.70 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.36 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $19.47 | 2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $18.49 | 2024 | |
| Orphalan INC | $18.28 | 2025 | Cuvrior |
| Novo Nordisk INC | $17.17 | 2025 | Wegovy, Saxenda |
| Lilly USA, LLC | $13.76 | 2025 | Omvoh |
| Alnylam Pharmaceuticals INC. | $13.51 | 2025 | Givlaari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hamid Ullah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.